» Articles » PMID: 23816557

Re-evaluation of ABO Gene Polymorphisms Detected in a Genome-wide Association Study and Risk of Pancreatic Ductal Adenocarcinoma in a Chinese Population

Overview
Journal Chin J Cancer
Publisher Biomed Central
Specialty Oncology
Date 2013 Jul 3
PMID 23816557
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic cancer is a fatal malignancy with an increasing incidence in Shanghai, China. A genome-wide association study (GWAS) and other work have shown that ABO alleles are associated with pancreatic cancer risk. We conducted a population-based case-control study involving 256 patients with pathologically confirmed pancreatic ductal adenocarcinoma (PDAC) and 548 healthy controls in Shanghai, China, to assess the relationships between GWAS-identified ABO alleles and risk of PDAC. Carriers of the C allele of rs505922 had an increased cancer risk [adjusted odds ratio (OR) = 1.42, 95% confidence interval (CI): 1.02-1.98] compared to TT carriers. The T alleles of rs495828 and rs657152 were also significantly associated with an elevated cancer risk (adjusted OR = 1.58, 95% CI: 1.17-2.14; adjusted OR = 1.51, 95% CI: 1.09-2.10). The rs630014 variant was not associated with risk. We did not find any significant gene-environment interaction with cancer risk using a multifactor dimensionality reduction (MDR) method. Haplotype analysis also showed that the haplotype CTTC was associated with an increased risk of PDAC (adjusted OR = 1.46, 95% CI: 1.12-1.91) compared with haplotype TGGT. GWAS-identified ABO variants are thus also associated with risk of PDAC in the Chinese population.

Citing Articles

A systematic review and network meta-analysis of single nucleotide polymorphisms associated with pancreatic cancer risk.

Ye Z, Li L, Luo M, Qing H, Zheng J, Zhang C Aging (Albany NY). 2020; 12(24):25256-25274.

PMID: 33226370 PMC: 7803556. DOI: 10.18632/aging.104128.


A comprehensive assessment of single nucleotide polymorphisms associated with pancreatic cancer risk: A protocol for systematic review and network meta-analysis.

Ye Z, Li L, Zheng J, Zhang C, Lu Y, Tang Y Medicine (Baltimore). 2020; 99(24):e20345.

PMID: 32541456 PMC: 7302655. DOI: 10.1097/MD.0000000000020345.


Association of ABO polymorphisms and pancreatic Cancer/ Cardiocerebrovascular disease: a meta-analysis.

Li Y, Liu L, Huang Y, Zheng H, Li L BMC Med Genet. 2020; 21(1):41.

PMID: 32093636 PMC: 7041112. DOI: 10.1186/s12881-020-0975-8.


Inherited pancreatic cancer.

Chen F, Roberts N, Klein A Chin Clin Oncol. 2018; 6(6):58.

PMID: 29307198 PMC: 5873957. DOI: 10.21037/cco.2017.12.04.


Associations between ABO blood groups and pancreatic ductal adenocarcinoma: influence on resection status and survival.

El Jellas K, Hoem D, Hagen K, Kalvenes M, Aziz S, Steine S Cancer Med. 2017; 6(7):1531-1540.

PMID: 28556564 PMC: 5504338. DOI: 10.1002/cam4.1097.


References
1.
Han H, Von Hoff D . SnapShot: pancreatic cancer. Cancer Cell. 2013; 23(3):424-424.e1. PMC: 3638898. DOI: 10.1016/j.ccr.2013.03.008. View

2.
Bardeesy N, DePinho R . Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002; 2(12):897-909. DOI: 10.1038/nrc949. View

3.
Lin D, Zeng D, Millikan R . Maximum likelihood estimation of haplotype effects and haplotype-environment interactions in association studies. Genet Epidemiol. 2005; 29(4):299-312. DOI: 10.1002/gepi.20098. View

4.
Amundadottir L, Kraft P, Stolzenberg-Solomon R, Fuchs C, Petersen G, Arslan A . Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009; 41(9):986-90. PMC: 2839871. DOI: 10.1038/ng.429. View

5.
Egberts J, Cloosters V, Noack A, Schniewind B, Thon L, Klose S . Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008; 68(5):1443-50. DOI: 10.1158/0008-5472.CAN-07-5704. View